NASDAQ:NRBO NeuroBo Pharmaceuticals (NRBO) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free NRBO Stock Alerts $3.10 +0.04 (+1.31%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$3.01▼$3.1050-Day Range$3.02▼$6.5252-Week Range$2.89▼$6.75Volume17,307 shsAverage Volume25,355 shsMarket Capitalization$15.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get NeuroBo Pharmaceuticals alerts: Email Address NeuroBo Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.63% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.51Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.50) to ($2.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.14 out of 5 starsMedical Sector760th out of 913 stocksPharmaceutical Preparations Industry352nd out of 423 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for NeuroBo Pharmaceuticals. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.63% of the float of NeuroBo Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverNeuroBo Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroBo Pharmaceuticals has recently decreased by 16.16%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeuroBo Pharmaceuticals does not currently pay a dividend.Dividend GrowthNeuroBo Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NRBO. Previous Next 3.1 News and Social Media Coverage News SentimentNeuroBo Pharmaceuticals has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for NeuroBo Pharmaceuticals this week, compared to 1 article on an average week.MarketBeat Follows1 people have added NeuroBo Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeuroBo Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.79% of the stock of NeuroBo Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 1.37% of the stock of NeuroBo Pharmaceuticals is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for NeuroBo Pharmaceuticals are expected to grow in the coming year, from ($3.50) to ($2.22) per share.Price to Book Value per Share RatioNeuroBo Pharmaceuticals has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About NeuroBo Pharmaceuticals Stock (NASDAQ:NRBO)NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Read More NRBO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRBO Stock News HeadlinesApril 27, 2024 | americanbankingnews.comNeuroBo Pharmaceuticals, Inc. Forecasted to Earn FY2024 Earnings of ($3.83) Per Share (NASDAQ:NRBO)April 26, 2024 | americanbankingnews.comNeuroBo Pharmaceuticals, Inc. Forecasted to Earn Q1 2024 Earnings of ($0.95) Per Share (NASDAQ:NRBO)April 27, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. April 25, 2024 | americanbankingnews.comNeuroBo Pharmaceuticals (NASDAQ:NRBO) Trading Up 2.6%April 23, 2024 | finance.yahoo.comNRBO: First Patient Dosed in Phase 1 Trial of DA-1726 for the Treatment of Obesity…April 19, 2024 | americanbankingnews.comHead to Head Review: NeuroBo Pharmaceuticals (NASDAQ:NRBO) vs. Ainos (NASDAQ:AIMD)April 17, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityApril 17, 2024 | prnewswire.comNeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityApril 27, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. April 5, 2024 | morningstar.comNeuroBo Pharmaceuticals Inc NRBOApril 1, 2024 | prnewswire.comNeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHMarch 28, 2024 | finanznachrichten.deNeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate UpdateMarch 28, 2024 | prnewswire.comNeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate UpdateMarch 13, 2024 | markets.businessinsider.comNeuroBo Pharma Gets Approval To Proceed With Phase 2a Trial For DA-1241 To Treat MASH; Stock Up 8%March 13, 2024 | prnewswire.comNeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHMarch 4, 2024 | finanznachrichten.deNeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial OfficerMarch 4, 2024 | msn.comNeuroBo Pharmaceuticals appoints Marshall Woodworth as CFOMarch 4, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals Confirms Marshall Woodworth As New CFOMarch 4, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial OfficerFebruary 29, 2024 | markets.businessinsider.comNeuroBo Receives First Site IRB Approval For DA-1726 Obesity Trial; Stock GainsFebruary 29, 2024 | prnewswire.comNeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityFebruary 12, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor ConferenceFebruary 6, 2024 | finance.yahoo.comNRBO: Initiating Coverage of NeuroBo Pharmaceuticals, Inc.; Targeting the $30 Billion+ Obesity Market…February 2, 2024 | msn.comNeuroBo’s DA-1726 Obesity Therapy Gets FDA IND ApprovalFebruary 1, 2024 | msn.comWhy Obesity-Drug Maker NeuroBo Stock Is Trading HigherFebruary 1, 2024 | markets.businessinsider.comNeuroBo Pharma'a IND Application For DA-1726 Gets FDA ClearanceFebruary 1, 2024 | markets.businessinsider.comNeuroBo Rises 48% On Receiving FDA Approval For IND Application For DA-1726See More Headlines Receive NRBO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroBo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today4/27/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NRBO CUSIPN/A CIK1638287 Webwww.neurobopharma.com Phone(857) 702-9600Fax734-293-0444Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-59.42% Return on Assets-45.40% Debt Debt-to-Equity RatioN/A Current Ratio3.78 Quick Ratio3.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.44 per share Price / Book0.90Miscellaneous Outstanding Shares4,910,000Free Float4,867,000Market Cap$15.22 million OptionableNot Optionable Beta-0.25 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Hyung-Heon Kim (Age 49)CEO, President, Principal Executive & Director Comp: $54.22kMr. Marshall H. Woodworth (Age 66)CFO, Principal Financial Officer & Principal Accounting Officer Dr. Mi-Kyung KimChief Scientific OfficerMr. Robert HomolkaSenior Vice President of Clinical OperationsKey CompetitorsAytu BioPharmaNASDAQ:AYTUKiora PharmaceuticalsNASDAQ:KPRXEdesa BiotechNASDAQ:EDSAABVC BioPharmaNASDAQ:ABVCTraws PharmaNASDAQ:TRAWView All Competitors NRBO Stock Analysis - Frequently Asked Questions How have NRBO shares performed in 2024? NeuroBo Pharmaceuticals' stock was trading at $3.70 at the beginning of the year. Since then, NRBO stock has decreased by 16.2% and is now trading at $3.10. View the best growth stocks for 2024 here. Are investors shorting NeuroBo Pharmaceuticals? NeuroBo Pharmaceuticals saw a decline in short interest in April. As of April 15th, there was short interest totaling 51,900 shares, a decline of 16.2% from the March 31st total of 61,900 shares. Based on an average daily volume of 1,290,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 2.6% of the shares of the stock are sold short. View NeuroBo Pharmaceuticals' Short Interest. When is NeuroBo Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our NRBO earnings forecast. How were NeuroBo Pharmaceuticals' earnings last quarter? NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) posted its quarterly earnings results on Monday, November, 15th. The company reported ($38.40) EPS for the quarter, beating the consensus estimate of ($43.20) by $4.80. When did NeuroBo Pharmaceuticals' stock split? NeuroBo Pharmaceuticals shares reverse split on the morning of Thursday, December 21st 2023. The 1-8 reverse split was announced on Thursday, December 21st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What other stocks do shareholders of NeuroBo Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroBo Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Cumberland Pharmaceuticals (CPIX), Akero Therapeutics (AKRO), Chimerix (CMRX), Trevena (TRVN), VBI Vaccines (VBIV), VIVUS (VVUS) and Aldeyra Therapeutics (ALDX). How do I buy shares of NeuroBo Pharmaceuticals? Shares of NRBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NRBO) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroBo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
